{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-083126","form_type":"8-K","ticker":"COLL","cik":"0001267565","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2024-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.427236+00:00","generated_at":"2026-05-31T15:39:16.835234+00:00","sec_items":["1.01","2.02","2.03","5.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Collegium to acquire Ironshore Therapeutics for $525M; Jornay PM ADHD drug; Q2 prelim rev $145M","bullets":["Acquires Ironshore for $525M cash plus up to $25M milestone if Jornay PM net revenue exceeds defined 2025 threshold.","Jornay PM (ADHD) expected >$100M net revenue in 2024; H1 2024 prescriptions up 32% YoY.","Funded by cash on hand and new $646M five-year Pharmakon loan with 300bps rate reduction.","Preliminary Q2 2024 net product revenue $145M (+7% YoY); reaffirms FY2024 guidance of $580-595M revenue, $380-395M adj EBITDA.","Director Neil McFarlane resigned immediately due to conflict of interest (CEO of Zevra Therapeutics)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-083126","json":"https://secwatch.observer/filing/0001104659-24-083126.json","markdown":"https://secwatch.observer/filing/0001104659-24-083126.md","text":"https://secwatch.observer/filing/0001104659-24-083126.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1267565/000110465924083126/0001104659-24-083126-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1267565/000110465924083126/tm2420341d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T15:39:16.835234+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4bc9b429e5","claim":"Neil McFarlane resigned as director at COLLEGIUM PHARMACEUTICAL, INC.","evidence_excerpt":"On July 28, 2024, Neil McFarlane notified the board of directors of the Company (the “Board”) of his intent to resign from the Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465924083126/0001104659-24-083126-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}